TD Asset Management Inc Has $9.14 Million Position in Repligen Corporation $RGEN

TD Asset Management Inc increased its holdings in Repligen Corporation (NASDAQ:RGEN) by 109.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,756 shares of the biotechnology company’s stock after purchasing an additional 29,128 shares during the period. TD Asset Management Inc owned approximately 0.10% of Repligen worth $9,136,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Measured Wealth Private Client Group LLC bought a new stake in Repligen during the third quarter worth approximately $29,000. Bayforest Capital Ltd acquired a new position in Repligen during the 4th quarter valued at $32,000. Rachor Investment Advisory Services LLC bought a new stake in Repligen in the 4th quarter valued at $33,000. Farther Finance Advisors LLC grew its position in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares during the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in Repligen in the 3rd quarter valued at approximately $65,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Price Performance

NASDAQ RGEN opened at $130.13 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The business has a 50 day simple moving average of $119.28 and a 200 day simple moving average of $138.32. The stock has a market cap of $7.34 billion, a price-to-earnings ratio of 144.59, a PEG ratio of 2.42 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period last year, the business posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. UBS Group lowered their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. HC Wainwright boosted their target price on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 7th. Roth Mkm started coverage on Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 target price on the stock. Finally, Royal Bank Of Canada began coverage on shares of Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $164.64.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.